Un ensayo prospectivo, multicéntrico, aleatorizado y controlado para investigar el valor de la angiografía por tomografía computarizada coronaria en la comprensión y el manejo del calcio coronario (El ensayo Óptimo)
9 de noviembre de 2026 actualizado por: Fundación EPIC
Un Ensayo Prospectivo, Multicéntrico, Aleatorizado y Controlado para Investigar el Valor de la Angiografía por Tomografía Computarizada Coronaria en la Comprensión y Manejo del Calcio Coronario
The OPTIMAL randomized clinical trial has been designed to compare two imaging strategies and to test the hypothesis that a calcium modification strategy informed by coronary CT angiography (CCTA) will improve procedural efficiency and effectiveness compared with the current standard of care (IVUS-guided PCI) while achieving similar clinical outcomes in patients with hemodynamically significant calcified coronary artery disease.
Descripción general del estudio
Estado
Estado
Reclutamiento
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
The OPTIMAL Trial is a prospective, multicenter, randomized controlled study evaluating whether a coronary CT angiography (CCTA)-guided calcium modification strategy can improve the treatment of patients with hemodynamically significant, calcified coronary artery disease undergoing percutaneous coronary intervention (PCI).
Seven hundred patients with flow-limiting stenosis (FFRCT ≤0.80) and moderate-to-severe calcification on CCTA will be randomized 1:1 to either CCTA-guided or intravascular ultrasound (IVUS)-guided calcium modification. The study includes two co-primary endpoints: (1) superiority in final minimal stent area assessed by IVUS, and (2) non-inferiority in 12-month target vessel failure (cardiac death, target-vessel myocardial infarction, or ischemia-driven revascularization).
CCTA-guided strategy uses advanced calcium characterization to inform pre-procedural planning and selection of plaque modification techniques. IVUS-guided strategy follows contemporary intravascular imaging-based criteria for plaque preparation and PCI optimization.
The trial aims to determine whether leveraging non-invasive CT-based calcium assessment can enhance procedural efficiency and stent results while maintaining clinical safety comparable to IVUS-guided PCI.
Tipo de estudio
Tipo de estudio
Intervencionista
Inscripción (Estimado)
Inscripción
700
Fase
Fase
- No aplica
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Estudio Contacto
Estudio Contacto
- Nombre: CAROLINA FOCELLA
- Número de teléfono: 001 917 753 6695
- Correo electrónico: cfocella@crf.org
Copia de seguridad de contactos de estudio
- Nombre: CARLOS COLLET, MD,PhD
- Número de teléfono: 001 917 753 6695
- Correo electrónico: carloscollet@gmail.com
Ubicaciones de estudio
-
-
-
Aalst, Bélgica, 9300
- Reclutamiento
- Azorg Hospital, Aalst
-
-
-
-
-
Barcelona, España, 08035
- Reclutamiento
- Hospital Universitari Vall Hebron
-
León, España
- Reclutamiento
- Hospital Universitario de Leon
-
Madrid, España, 28046
- Reclutamiento
- Hospital Universitario La Paz
-
-
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02115
- Aún no reclutando
- Bringham and Women's Hospital
-
-
Minnesota
-
Minneapolis, Minnesota, Estados Unidos, 55407
- Reclutamiento
- Minneapolis Heart Institute
-
-
New Jersey
-
Jersey City, New Jersey, Estados Unidos, 08837
- Aún no reclutando
- HACKENSACK MERIDIAN HEALTH, Inc
-
-
New York
-
New York, New York, Estados Unidos, 14853
- Aún no reclutando
- Weill Medical College of Cornell University
-
New York, New York, Estados Unidos, 10032
- Reclutamiento
- NewYork-Presbyterian/Weill Cornell Medical Center
-
-
-
-
-
Leicester, Reino Unido
- Reclutamiento
- University Hospitals of Leicester NHS Trust
-
London, Reino Unido
- Reclutamiento
- St Bartholomew's Hospital (Barts Health NHS Trust)
-
London, Reino Unido
- Reclutamiento
- St George's University Hospitals NHS Foundations Trust
-
Contacto:
- James Spratt, MD, PhD
-
London, Reino Unido
- Reclutamiento
- Guys & St Thomas Nhs Foundation Trust
-
Newcastle, Reino Unido
- Aún no reclutando
- Newcastle Hospitals NHS Foundations Trust
-
Oxford, Reino Unido
- Aún no reclutando
- John Radcliffe Hospital, Oxford
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
18 años a 85 años (Adulto, Adulto Mayor)
Acepta Voluntarios Saludables
No
Géneros elegibles para el estudio
Todos
Descripción
Inclusion Criteria:
- The subject must be at least 18 years of age and younger than 85 years old
- Subject must have evidence of myocardial ischemia (e.g., stable angina, silent ischemia (ischemia in the absence of chest pain or other anginal equivalents), unstable angina, or acute myocardial infarction) suitable for PCI. Patients with a clinical indication for revascularization presenting with stable coronary artery disease or stabilized acute coronary syndrome defined as follows unstable angina (Braunwald class IB, IC, IIB, IIC, IIIB, IIIC), patients with NSTEMI without high-risk features such as recurrence of chest pain, ST-segment depression>1mm in ≥6 leads plus STsegment elevation in aVR, life-threatening arrhythmias, mechanical complications of MI, resuscitated cardiac arrest, GRACE risk score>140.
- All target vessels must have reference vessel diameter (visually assessed by CCTA) ≥ 2.5 mm
- Subject must provide written informed consent before any study-related procedure
Exclusion Criteria:
- STEMI as the clinical presentation.
- Uncontrolled or recurrent ventricular tachycardia.
- Hemodynamic instability.
- Hemodialysis or peritoneal dialysis.
- Left main coronary artery stenosis > 50%
- Atrial fibrillation, flutter, or arrhythmias during CT acquisition.
- Previous PCI in the target vessel or CABG.
- BMI ≥ 40 kg/m2
- Insufficient CT quality assessed by the Core lab.
- Comorbidity with life expectancy ≤ 2 years.
- Planned major cardiac or non-cardiac surgery within 24 months after the index procedure Note: Major surgery is any invasive operative procedure in which an extensive resection is performed, e.g., a body cavity is entered, organs are removed, or normal anatomy is altered. Note: Minor surgery is an operation on the superficial structures of the body or a manipulative procedure that does not involve a serious risk. Planned minor surgery is not excluded.
- The subject has received a solid organ transplant that is functioning or is active on a waiting list for any solid organ transplants with expected transplantation within 24 months.
- The subject receives immunosuppressant therapy or has known immunosuppressive or severe autoimmune disease that requires chronic immunosuppressive therapy (e.g., human immunodeficiency virus, systemic lupus erythematosus, etc.). Note: corticosteroids are not included as immunosuppressant therapy.
- The subject has previously received or is scheduled to receive radiotherapy to a coronary artery (vascular brachytherapy) or the chest/mediastinum.
- Subject has a platelet count <100,000 cells/mm3 or >700,000 cells/mm3.
- The subject has a documented or suspected hepatic disorder as defined as cirrhosis or Child-Pugh ≥ Class B.
- The subject has a history of bleeding diathesis or coagulopathy or has had a significant gastro-intestinal or significant urinary bleed within the past six months. The subject has had a cerebrovascular accident or transient ischemic neurological attack (TIA) within the past six months, or any prior intracranial bleed, or any permanent neurologic defect, or any known intracranial pathology (e.g., aneurysm, arteriovenous malformation, etc. The subject has a life expectancy <2 years for any non-cardiac cause.
- Subject is currently participating in another investigational drug or device clinical study.
- Pregnant or nursing subjects and those who plan pregnancy in the period up to 2 years following index procedure. Female subjects of child-bearing potential must have a negative pregnancy test done within 7 days prior to the index procedure per site standard test.
- Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results.
- Unable to provide written informed consent (IC).
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Número de brazos
2
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: CT-guide calcium modification strategy
Pre-procedural CT will be used to determine lesion characteristics. |
CT will be used to determine lesion characteristics and post-procedural IVUS to confirm correct implantation of stent |
|
Comparador activo: IVUS-guide calcium modification strategy
Pre-procedural IVUS will be used to determine lesion characteristics. |
IVUS will be used to determine lesion characteristics and post-procedural IVUS to confirm correct implantation of stent |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Demonstrate that CT-guided calcium modification results in a superior final MSA Minimal Stent Area (MSA) - Imaging Endpoint (Superiority)
Periodo de tiempo: Perioperative/Periprocedural
|
Final post-PCI minimal stent area per target lesion, measured by independent core laboratory using intravascular ultrasound (IVUS). Assesses whether CT-guided calcium modification results in superior stent expansion compared with IVUS-guided PCI. |
Perioperative/Periprocedural
|
|
Target Vessel Failure (TVF) - Clinical Endpoint (Non-Inferiority)
Periodo de tiempo: 12 months
|
Composite of cardiac death, target-vessel myocardial infarction (TV-MI), or ischemia-driven target vessel revascularization (ID-TVR). TV-MI and ID-TVR are defined according to ARC-2 and the Fourth Universal Definition of MI. |
12 months
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Procedural efficiency: Procedure time
Periodo de tiempo: During PCI
|
Time from first angiogram to final angiogram |
During PCI
|
|
Procedural efficiency:Radiation dose-area product
Periodo de tiempo: During PCI
|
Dose-area product (DAP) recorded during PCI. |
During PCI
|
|
Procedural efficiency: Contrast volume
Periodo de tiempo: During PCI
|
Total contrast volume (mL) used during PCI.IVUS-Derived Mechanistic Endpoints (Core Lab) |
During PCI
|
|
Procedural Efficiency: Stent Area on Immediate Post-Stent IVUS
Periodo de tiempo: Perioperative/Periprocedural
|
MSA prior to any final IVUS-guided optimization. |
Perioperative/Periprocedural
|
|
Procedural Efficiency: Final Stent Area at Original Minimal Lumen Area (MLA)
Periodo de tiempo: Perioperative/Periprocedural
|
Stent area at the co-registered site of the baseline MLA. |
Perioperative/Periprocedural
|
|
Procedural Efficiency: Final Stent Area at Site of Maximum Calcium Arc
Periodo de tiempo: Perioperative/Periprocedural
|
Stent area measured at the co-registered IVUS site with maximal calcium arc |
Perioperative/Periprocedural
|
|
Procedural Efficiency: Final Stent Area at Site of Maximum Calcium Density
Periodo de tiempo: Perioperative/Periprocedural
|
Stent area measured at the co-registered CT-identified region of greatest Hounsfield Unit (HU) calcium density. |
Perioperative/Periprocedural
|
|
Procedural Efficiency: Relative Stent Expansion
Periodo de tiempo: Perioperative/Periprocedural
|
Percentage expansion calculated as: MSA ÷ mean distal reference lumen area × 100. |
Perioperative/Periprocedural
|
|
Procedural Efficiency: Number of Calcium Fractures
Periodo de tiempo: Post-modification, pre-stent
|
Fractures identified on intermediary IVUS after calcium modification. |
Post-modification, pre-stent
|
|
Procedural Efficiency: Change in Plaque Attenuation
Periodo de tiempo: Post-modification, pre-stent
|
Change in IVUS plaque characteristics following calcium modification.Angiographic Endpoints |
Post-modification, pre-stent
|
|
Procedural Efficiency: Final Minimal Lumen Diameter
Periodo de tiempo: Perioperative/Periprocedural
|
Minimum lumen diameter by quantitative coronary angiography (QCA) |
Perioperative/Periprocedural
|
|
Procedural Efficiency: Final Percent Diameter Stenosis
Periodo de tiempo: Perioperative/Periprocedural
|
Percent stenosis of treated lesion after PCI, by QCA |
Perioperative/Periprocedural
|
|
Procedural Efficiency: Final TIMI Flow Grade
Periodo de tiempo: Perioperative/Periprocedural
|
Target vessel flow graded 0-3 based on TIMI criteria. Thrombolysis In Myocardial Infarction (TIMI) Flow Grade is a 0-3 angiographic scale used during coronary angiography to describe how well blood is flowing through a coronary artery.TIMI 0 No perfusion, TIMI 1 Penetration without perfusion, TIMI 2 Partial perfusion TIMI 3 Complete perfusion (normal flow) |
Perioperative/Periprocedural
|
|
Procedural Efficiency: Angiographic Complications
Periodo de tiempo: Day of procedure
|
According to Coronary dissection (NHLBI classification) |
Day of procedure
|
|
Procedural Efficiency: Angiographic Complications
Periodo de tiempo: Day of procedure
|
According to Coronary perforation (Ellis classification) |
Day of procedure
|
|
Procedural Efficiency: Angiographic Complications
Periodo de tiempo: Day of procedure
|
Slow-flow / no-reflow |
Day of procedure
|
|
Procedural Efficiency: Angiographic Complications
Periodo de tiempo: Day of procedure
|
Side branch closure (TIMI 0-1) |
Day of procedure
|
|
Clinical & Safety Outcomes: Procedural Success
Periodo de tiempo: Perioperative/Periprocedural
|
Final stenosis <30%, TIMI 3 flow, no angiographic complications, and no in-hospital major adverse cardiac events (MACE). |
Perioperative/Periprocedural
|
|
Clinical & Safety Outcomes: Periprocedural Myocardial Infarction (Type 4a MI)
Periodo de tiempo: Day 0-1
|
Defined by ARC-2 and 4th Universal Definition of MI (troponin criteria + evidence of ischemia). |
Day 0-1
|
|
Clinical & Safety Outcomes: Stent Thrombosis
Periodo de tiempo: Up to 12 months
|
Definite or probable stent thrombosis according to ARC-2 definitions. |
Up to 12 months
|
|
Patient-Reported Outcomes: Residual Angina (SAQ-7 Angina Frequency)
Periodo de tiempo: 12 months
|
Residual angina defined as SAQ-7 Angina Frequency score <100. Angina frequency represent how often a patient has had angina (chest pain/discomfort) over a recent recall period. Reported as a 0 to 100 scale: 100 = no angina; 0 = angina occurring very frequently |
12 months
|
|
Patient-Reported Outcomes: Change in Angina (SAQ-7)
Periodo de tiempo: Baseline to 12 months
|
Change in angina frequency domain score; positive values indicate improvement. Angina frequency represent how often a patient has had angina (chest pain/discomfort) over a recent recall period. Reported as a 0 to 100 scale: 100 = no angina; 0 = angina occurring very frequently |
Baseline to 12 months
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Publicaciones y enlaces útiles
La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.
Publicaciones Generales
- Collet C, Sonck J, Vandeloo B, Mizukami T, Roosens B, Lochy S, Argacha JF, Schoors D, Colaiori I, Di Gioia G, Kodeboina M, Suzuki H, Van 't Veer M, Bartunek J, Barbato E, Cosyns B, De Bruyne B. Measurement of Hyperemic Pullback Pressure Gradients to Characterize Patterns of Coronary Atherosclerosis. J Am Coll Cardiol. 2019 Oct 8;74(14):1772-1784. doi: 10.1016/j.jacc.2019.07.072.
- Sonck J, Nagumo S, Norgaard BL, Otake H, Ko B, Zhang J, Mizukami T, Maeng M, Andreini D, Takahashi Y, Jensen JM, Ihdayhid A, Heggermont W, Barbato E, Mileva N, Munhoz D, Bartunek J, Updegrove A, Collinsworth A, Penicka M, Van Hoe L, Leipsic J, Koo BK, De Bruyne B, Collet C. Clinical Validation of a Virtual Planner for Coronary Interventions Based on Coronary CT Angiography. JACC Cardiovasc Imaging. 2022 Jul;15(7):1242-1255. doi: 10.1016/j.jcmg.2022.02.003. Epub 2022 Apr 13.
- Tajima A, Bouisset F, Ohashi H, Sakai K, Mizukami T, Rizzini ML, Gallo D, Chiastra C, Morbiducci U, Ali ZA, Spratt JC, Ando H, Amano T, Kitslaar P, Wilgenhof A, Sonck J, De Bruyne B, Collet C. Advanced CT Imaging for the Assessment of Calcific Coronary Artery Disease and PCI Planning. J Soc Cardiovasc Angiogr Interv. 2024 Mar 26;3(3Part B):101299. doi: 10.1016/j.jscai.2024.101299. eCollection 2024 Mar.
- Monizzi G, Sonck J, Nagumo S, Buytaert D, Van Hoe L, Grancini L, Bartorelli AL, Vanhoenacker P, Simons P, Bladt O, Wyffels E, De Bruyne B, Andreini D, Collet C. Quantification of calcium burden by coronary CT angiography compared to optical coherence tomography. Int J Cardiovasc Imaging. 2020 Dec;36(12):2393-2402. doi: 10.1007/s10554-020-01839-z. Epub 2020 Nov 17.
- Collet C, Collison D, Mizukami T, McCartney P, Sonck J, Ford T, Munhoz D, Berry C, De Bruyne B, Oldroyd K. Differential Improvement in Angina and Health-Related Quality of Life After PCI in Focal and Diffuse Coronary Artery Disease. JACC Cardiovasc Interv. 2022 Dec 26;15(24):2506-2518. doi: 10.1016/j.jcin.2022.09.048. Epub 2022 Nov 30.
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
22 de diciembre de 2025
Finalización primaria (Estimado)
Finalización primaria
15 de diciembre de 2029
Finalización del estudio (Estimado)
Finalización del estudio
1 de enero de 2030
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
28 de noviembre de 2025
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
12 de diciembre de 2025
Publicado por primera vez (Actual)
Publicado por primera vez
16 de diciembre de 2025
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
10 de noviembre de 2026
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
9 de noviembre de 2026
Última verificación
Última verificación
1 de noviembre de 2026
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
Otros números de identificación del estudio
- EPIC46-THE OPTIMAL TRIAL
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
No
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
No
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .